Abbott Laboratories (ABT) operating KPIs
ABTNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 28, 2026Score 14/3036% above fair value
$106.20+1.63 (+1.56%)
Close on Oct 30, 2026Market cap $183.77BP/E 34.1Yield 2.26%
Abbott Laboratories electrophysiology Division (Volt PFA, TactiFlex Duo, EnSite X Cardiac Mapping) — Worldwide Revenue ($M) ($M)
Form 8-K Quarterly Earnings Releases (Item 2.02 Revenue Tables) & Form 10-K/10-Q MD&A
Latest, FY2025
2,764
Period ended Dec 31, 2025
Change on a year earlier
+12.0%
2,467 in FY2024
History
10 years
Since FY2016
Sources
10
Documents cited below
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Electrophysiology Division (Volt PFA, TactiFlex Duo, EnSite X Cardiac Mapping) — Worldwide Revenue ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 2,764 | +12.0% | SEC Filing (0001628280-26-002982) ↗ |
| FY2024 | Dec 31, 2024 | 2,467 | +12.4% | SEC Filing (0001628280-25-002092) ↗ |
| FY2023 | Dec 31, 2023 | 2,195 | +13.9% | SEC Filing (0001628280-24-002009) ↗ |
| FY2022 | Dec 31, 2022 | 1,927 | +1.0% | SEC Filing (0001628280-23-001516) ↗ |
| FY2021 | Dec 31, 2021 | 1,907 | +20.8% | SEC Filing (0001104659-22-007648) ↗ |
| FY2020 | Dec 31, 2020 | 1,578 | -8.3% | SEC Filing (0001104659-21-007942) ↗ |
| FY2019 | Dec 31, 2019 | 1,721 | +3.2% | SEC Filing (0001104659-20-005717) ↗ |
| FY2018 | Dec 31, 2018 | 1,668 | +20.7% | SEC Filing (0001104659-19-002848) ↗ |
| FY2017 | Dec 31, 2017 | 1,382 | +11.9% | SEC Filing (0001104659-18-003691) ↗ |
| FY2016 | Dec 31, 2016 | 1,235 | – | SEC Filing (0001104659-17-023826) ↗ |
Breakdown
What makes up electrophysiology division (volt pfa, tactiflex duo, ensite x cardiac mapping) — worldwide revenue ($m)
- Electrophysiology Division (Volt PFA, TactiFlex Duo, EnSite X Cardiac Mapping) — Organic / Comparable Sales Growth (%)11.6% · FY2025
- Electrophysiology Division (Volt PFA, TactiFlex Duo, EnSite X Cardiac Mapping) — Reported Sales Growth (%)12.0% · FY2025
- Electrophysiology Division (Volt PFA, TactiFlex Duo, EnSite X Cardiac Mapping) — Foreign Exchange Impact on Sales Growth (%)0.4% · FY2025
- Electrophysiology Division (Volt PFA, TactiFlex Duo, EnSite X Cardiac Mapping) — U.S. Revenue ($M)1,283 · FY2025
- Electrophysiology Division (Volt PFA, TactiFlex Duo, EnSite X Cardiac Mapping) — International Revenue ($M)1,481 · FY2025
Cite this data
StockData. (2026). Abbott Laboratories Electrophysiology Division (Volt PFA, TactiFlex Duo, EnSite X Cardiac Mapping) — Worldwide Revenue ($M) ($M), annual FY2016–FY2025 [Data set]. Compiled from Abbott Laboratories SEC filings and investor materials. https://stockdatahq.com/stocks/abt/kpis/md-ep-rev-ww
See every metric in the Abbott Laboratories KPI table. Data updated Oct 29, 2026.